NovMetaPharma
NovMetaPharma is a company that develops first-in-class drugs with differentiated mechanisms using new substances, focusing on metabolic diseases. They aim to lead the global market with innovative technology and efficient development systems. The company is engaged in developing medications for diabetes, obesity, kidney disease, fibrosis, and retroperitoneal fibrosis, with a mission to improve health and quality of life worldwide.
Industries
Nr. of Employees
small (1-50)
NovMetaPharma
727 Eonju-ro Trees Bldg., 13F Gangnam-gu, Seoul, South Korea
Patents
Composition comprising CHP (cyclo-his pro) for preventing, improving or treating of bone loss related disease
US-11975041-B2
View DetailsCell-protecting composition containing cyclo histidine-proline as active ingredient
US-11890317-B2
View DetailsPolymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease
US-11820834-B2
View DetailsPharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients
US-11607441-B2
View Details
Composition comprising CHP (cyclo-his pro) for preventing, improving or treating of bone loss related disease
US-11975041-B2
View DetailsCell-protecting composition containing cyclo histidine-proline as active ingredient
US-11890317-B2
View DetailsPolymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease
US-11820834-B2
View DetailsPharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients
US-11607441-B2
View DetailsProducts
Type 2 diabetes therapeutic candidate (first-in-class mechanism)
A small-molecule candidate developed to treat type 2 diabetes using a differentiated mechanism (AMPK/Sirt1/Nrf2 pathway activation); clinical progression includes Phase 1 and Phase 2 studies with Phase 2b dosing completed in the United States.
Anti-obesity therapeutic candidate
A therapeutic candidate targeting obesity developed as part of the metabolic disease portfolio with clinical Phase 1 and Phase 2a activity reported.
Acute pancreatitis therapeutic candidate (mitochondrial VDAC targeting)
A preclinical-to-early-clinical candidate that inhibits mitochondrial calcium channel (VDAC) transcription to improve mitochondrial dysfunction, ER stress and autophagy implicated in acute pancreatitis; development timeline indicates preclinical progressing to Phase 1/2a.
Alzheimer's disease therapeutic candidate (microglia activation / antioxidant)
A research-stage candidate aimed at enhancing microglial protein clearance and providing antioxidant protection to address degenerative brain disease pathology; preclinical progressing toward Phase 1/2a.
Liver cancer therapeutic candidate (ROS-mediated anti-proliferative mechanism)
A preclinical candidate that increases reactive oxygen species to induce cell cycle arrest (G1) in liver cancer cells and is being evaluated for combination use with tyrosine kinase inhibitors to address resistance.
Cytokine release syndrome cytokine inhibitor (research-stage)
A research-stage cytokine inhibitor candidate intended to reduce excessive cytokine release associated with infections and immune-mediated syndromes.
Type 2 diabetes therapeutic candidate (first-in-class mechanism)
A small-molecule candidate developed to treat type 2 diabetes using a differentiated mechanism (AMPK/Sirt1/Nrf2 pathway activation); clinical progression includes Phase 1 and Phase 2 studies with Phase 2b dosing completed in the United States.
Anti-obesity therapeutic candidate
A therapeutic candidate targeting obesity developed as part of the metabolic disease portfolio with clinical Phase 1 and Phase 2a activity reported.
Acute pancreatitis therapeutic candidate (mitochondrial VDAC targeting)
A preclinical-to-early-clinical candidate that inhibits mitochondrial calcium channel (VDAC) transcription to improve mitochondrial dysfunction, ER stress and autophagy implicated in acute pancreatitis; development timeline indicates preclinical progressing to Phase 1/2a.
Alzheimer's disease therapeutic candidate (microglia activation / antioxidant)
A research-stage candidate aimed at enhancing microglial protein clearance and providing antioxidant protection to address degenerative brain disease pathology; preclinical progressing toward Phase 1/2a.
Liver cancer therapeutic candidate (ROS-mediated anti-proliferative mechanism)
A preclinical candidate that increases reactive oxygen species to induce cell cycle arrest (G1) in liver cancer cells and is being evaluated for combination use with tyrosine kinase inhibitors to address resistance.
Cytokine release syndrome cytokine inhibitor (research-stage)
A research-stage cytokine inhibitor candidate intended to reduce excessive cytokine release associated with infections and immune-mediated syndromes.
Services
Joint research collaborations, technology transfers and co-development agreements with universities, hospitals and research institutes to advance discovery and translational programs.
Joint research collaborations, technology transfers and co-development agreements with universities, hospitals and research institutes to advance discovery and translational programs.
Expertise Areas
- Metabolic disease drug discovery
- Preclinical pharmacology and animal models
- Nonclinical toxicology and safety assessment
- Clinical trial management (Phase I–III)
Key Technologies
- Small‑molecule drug discovery
- Mechanism-based pathway modulation (AMPK, Sirt1, Nrf2)
- Mitochondrial-targeting compounds (VDAC modulation)
- Microglia-mediated protein clearance assays